An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution On May 13, Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Viridian Therapeutics Sees Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease On May 5, Viridian Therapeutics, Inc., announced positive topline data from the REVEAL‑2 phase 3 clinical trial of elegrobart in patients with chronic...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Shows Promise in Phase 3 Trial On April 28, Boehringer Ingelheim announced positive topline results from the Phase III SYNCHRONIZE-1 trial, in which survodutide (BI 456906) met the co-primary endpoints using both the efficacy...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Sanofi’s Tzield Approved in the US to Delay Onset of Stage 3 Type 1 Diabetes in Young Children The U.S. Food and Drug Administration (FDA) has approved the supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Amgen Announces Positive Top-Line Phase 3 Results for TED Treatment On April 6, Amgen announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active thyroid...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Foundayo™ Weight Loss GLP-1 Pill On April 1, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Novo Nordisk’s Awiqli® On March 26, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism On January 7, Rezolute, Inc., a late-stage rare disease company focused on treating hypoglycemia caused by all forms...
